Estados financieros detallados de Mineralys Therapeutics, Inc. (MLYS): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $27.54, MLYS presenta beneficios negativos (P/E no significativo) y un ROE del -57.97%. La capitalización bursátil es de $2.4B.
Cuenta de Resultados (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $2.4M | $16.3M | $26.2M | $70.4M | $168.6M | $132.0M |
| Generales y Administrativos | $532000 | $2.4M | $5.2M | $14.3M | $23.8M | $38.6M |
| Gastos Operativos | $2.9M | $18.7M | $31.5M | $84.7M | $192.4M | $170.6M |
| Beneficio Operativo | -$2.9M | -$18.7M | -$31.5M | -$84.7M | -$192.4M | -$170.6M |
| EBITDA | -$3.3M | -$19.4M | -$28.1M | -$71.9M | -$177.8M | -$154.6M |
| Gastos por Intereses | $115000 | $27000 | $1.7M | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$3.4M | -$19.4M | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$3.4M | -$19.4M | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
| BPA | $-0.74 | $-3.89 | $-5.77 | $-1.99 | $-3.66 | $-2.29 |
| BPA Diluido | $-0.74 | $-3.89 | $-5.77 | $-1.99 | $-3.66 | $-2.29 |
| Acciones en Circulación (Diluidas) | $4.6M | $5.0M | $5.2M | $36.2M | $48.5M | $67.7M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$15000 | 0 | -$6000 | 0 |
| Beneficio Operativo | -$41.1M | -$38.3M | -$45.3M | -$246.0M |
| EBITDA | -$36.9M | -$32.2M | -$39.3M | -$241.1M |
| Beneficio Neto | -$36.9M | -$32.2M | -$39.3M | -$241.1M |
| BPA | $-0.52 | $-0.40 | $-0.47 | $-2.85 |
| BPA Diluido | $-0.52 | $-0.40 | $-0.47 | $-2.85 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $1.4M | $10.6M | $87.7M | $49.3M | $114.1M | $172.9M |
| Inversiones a Corto | 0 | 0 | $22.4M | $187.3M | $84.1M | $483.7M |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $1.5M | $11.1M | $112.8M | $249.1M | $205.4M | $661.4M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | $53000 | $38000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $1.5M | $11.1M | $114.4M | $251.6M | $205.9M | $661.8M |
| Cuentas por Pagar | $529000 | $763000 | $1.9M | $601000 | $479000 | $2.0M |
| Deuda a Corto | $4.5M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $5.1M | $5.1M | $8.1M | $10.5M | $14.6M | $15.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $5.1M | $34.0M | $166.7M | $10.5M | $14.6M | $15.1M |
| Reservas | -$3.6M | -$23.0M | -$52.8M | -$124.7M | -$302.5M | -$457.2M |
| Patrimonio Neto | -$3.6M | -$22.9M | -$52.3M | $241.2M | $191.3M | $646.7M |
| Deuda Total | $4.5M | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | $3.1M | -$10.6M | -$110.1M | -$236.6M | -$198.2M | -$656.6M |
| Capital Circulante | -$3.6M | $6.1M | $104.7M | $238.6M | $190.7M | $646.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $217.6M | $172.9M | $112.8M | $138.3M |
| Activos Totales | $599.9M | $661.8M | $652.9M | $667.9M |
| Pasivos Totales | $23.5M | $15.1M | $14.7M | $116.9M |
| Patrimonio Neto | $576.4M | $646.7M | $638.1M | $550.9M |
| Deuda Total | 0 | 0 | 0 | $97.6M |
Flujo de Caja (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$3.4M | -$19.4M | -$29.8M | -$71.9M | -$177.8M | -$154.7M |
| Amortizaciones | 0 | 0 | 0 | 0 | $43000 | $59000 |
| Compensación en Acciones | $1000 | $80000 | $455000 | $5.1M | $11.3M | $19.3M |
| Cambio en Capital Circulante | $480000 | $4.1M | $772000 | -$7.5M | $9.5M | $2.7M |
| Flujo de Caja Operativo | -$2.5M | -$14.6M | -$29.2M | -$81.2M | -$166.3M | -$142.4M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | -$96000 | -$15000 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | -$1.6M | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.5M | -$14.6M | -$29.2M | -$81.2M | -$166.4M | -$142.4M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$28.9M | -$37.9M | -$39.5M | -$32.6M |
| Inversiones (CapEx) | 0 | -$15000 | 0 | 0 |
| Flujo de Caja Libre | -$28.9M | -$37.9M | -$39.5M | -$32.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $5.8M | $5.3M | $6.5M | $7.4M |
Crecimiento y Márgenes (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | -466.5% | -53.5% | -141.3% | -147.3% | +13.0% |
| Crecimiento BPA (anual) | | -425.7% | -48.3% | +65.5% | -83.9% | +37.4% |
| Cambio en Acciones (anual) | | +7.6% | +3.7% | +600.3% | +34.1% | +39.4% |
| Crecimiento FCF (anual) | | -491.1% | -100.7% | -177.8% | -105.0% | +14.4% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.53 | $-2.92 | $-5.65 | $-2.24 | $-3.43 | $-2.11 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $4.6M | $5.0M | $5.2M | $36.2M | $48.5M | $67.7M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -57.97% |
| Rentabilidad sobre capital invertido | -57.17% |
| Rentabilidad sobre activos | -52.34% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.18 |
| Ratio corriente | 34.46 |
Ratios Clave (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -24.92 | -4.74 | -3.20 | -4.32 | -3.36 | -15.85 |
| P/VC | -23.74 | -4.01 | -1.82 | 1.29 | 3.12 | 3.80 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |